November 2024 Kernel Newsletter

Q3 of 2024 was dominated by engagement with the scientific community around the work we’re doing at Kernel. Not only did we publish another study in Scientific Reports, we also presented updates on all aspects of our clinical development at several scientific conferences. As part of these presentations, we shared a first look at the interim results from our depression treatment response study, PREDICT. We’re incredibly encouraged by the trends in the data and the surrounding discussions with providers, payors, patients, and pharma.

The coming 6 months are lining up to be an exciting time in the demonstration of precision neuromedicine with our platform.

 

Ryan

CEO

www.kernel.com

Highlights

Clinical Research

Academic Engagements

Products and Services

Media Coverage

Clinical Research

MILD COGNITIVE IMPAIRMENT

After completing data collection on this study in June, we have been actively sharing the results and are currently preparing a manuscript for peer review. So far, we have presented our IMPACT results at:

  • Alzheimer’s Association International Conference (AAIC)
  • Meeting of the Society for Functional Near-Infrared Spectroscopy 
  • AAIC Advancements: Modernizing Diagnosis
  • European College of Neuropsychopharmacology (ECNP) Congress

Through each of these meetings, we were able to gain valuable feedback on our work and a clearer picture of how we can work to revolutionize the way cognition is measured. I shared a few of my thoughts within the context of Alzheimer’s Disease in a post shortly after the AAIC Advancements meeting.

The Kernel team is already planning our next step and expect to start collecting a new set of data in Q4 that will include a large cohort of healthy individuals to further this important area of research.

DEPRESSION

In Q3, we passed the halfway point of our transcranial magnetic stimulation (TMS) response prediction study with 30 patients having completed the full 6 week TMS protocol and all of the associated measurements with Kernel Flow.

We performed an interim readout of this data and shared the results at:

  • Meeting of the Society for Functional Near-Infrared Spectroscopy 
  • European College of Neuropsychopharmacology (ECNP) Congress

The top-line results show that 13 patients did not respond to treatment, 4 showed a response, and 13 achieved remission based on changes in their MADRS scores. Of these 30 patients, we can correctly predict their response to treatment with 87% accuracy from functional brain measurements before they have their first treatment session. These results could be game-changing for interventional psychiatry.

There are currently 50 TMS patients enrolled in the study and we are aiming to complete our target enrollment by the end of Q4.

Enrollment is also open for patients in our SPRAVATO treatment cohort. We have been forming new research partnerships with psychiatry clinics to accelerate this line of work.

Academic Engagements

NEW PUBLICATION

In addition to our core clinical work, Kernel also conducts studies to show the capabilities of our system. In July, our third peer-reviewed Scientific Reports article was published on Test/Retest reliability.

OTHER CONFERENCES

In addition to the clinical results we presented at conferences, we also shared our latest hardware designs at the Neuroergonomics conference, Society for Functional Near Infrared Spectroscopy conference, and participated in an industry panel on neurotechnology at the Neuroscience of the Everyday World conference. The key themes included increasing access to new tools for research and ultimately clinical use. We’re strong believers that the true value of research is only realized once patients have widespread access to and can benefit from the outcomes.

UPCOMING CONFERENCES

There are still many events before the end of the year and we’d be happy to connect! Kernel will be at:

  • Milken Institute Future of Health Summit in Washington, D.C. from 11/13 - 11/14
  • Roundtable of Longevity Clinics at The Buck Institute in the San Francisco area from 12/6 - 12/7
  • ACNP Annual Meeting in Phoenix from 12/8 - 12/11
Products and Services

PARTNERSHIPS

Kernel has been partnering with corporate research groups in biopharma, consumer products, and beyond. We’re expanding our research services offerings and will selectively engage in funded partnerships that span the range of research in psychoactive, neuropsychiatric, neurocognitive and neurodevelopmental interventions. Connect with us if you are interested in discussing how your product or intervention impacts the brain.

PURCHASING KERNEL HARDWARE

Have you ever seen Kernel’s work and thought “I’d really like to use an advanced tool like Flow to explore my own research questions”?

You’re not alone! More than a dozen research institutions, from private clinics to world-renowned universities, have started using Kernel Flow. Details on our systems and pricing are available on our products page. Not only are we transparent with pricing but we’re also much, much cheaper than any MRI scanner.

Media Coverage

© 2024 Kernel

If you do not wish to receive further communication like this, unsubscribe here.